AZD3470 at ASCO 2026: a promising new drug for Hodgkin lymphoma? - Clinical Trials Arena
AZD3470 at ASCO 2026: a promising new drug for Hodgkin lymphoma? Clinical Trials Arena
Hodgkin Lymphoma News
Study reveals promising new therapy for non-Hodgkin lymphoma - Medical Xpress
Study reveals promising new therapy for non-Hodgkin lymphoma Medical Xpress
Non-Hodgkins Lymphoma Market Trends and Insights - Precedence Research
Non-Hodgkins Lymphoma Market Trends and Insights Precedence Research
ASH 2025 Updates in Non-Hodgkin Lymphoma – Binaytara - Oncodaily
ASH 2025 Updates in Non-Hodgkin Lymphoma – Binaytara Oncodaily
Understanding the Origins of Hodgkin Lymphoma Cells Could Lead to Better Diagnostics - WCM Newsroom
Understanding the Origins of Hodgkin Lymphoma Cells Could Lead to Better Diagnostics WCM Newsroom
Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Sternberg cells reveals escape from NK cell recognition and an unfolded protein response | Blood Cancer Journal - Nature
Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Sternberg cells reveals escape from NK cell recognition and an unfolded protein response | Blood Cancer Journal Nature
New treatment combination offers excellent results for early-stage Hodgkin lymphoma with less chemotherapy - UT MD Anderson
New treatment combination offers excellent results for early-stage Hodgkin lymphoma with less chemotherapy UT MD Anderson
Ureteral Involvement in Non-Hodgkin Lymphoma: A Rare Case Report With Diagnostic Challenges - Cureus
Ureteral Involvement in Non-Hodgkin Lymphoma: A Rare Case Report With Diagnostic Challenges Cureus
FDA Approves Nivolumab Plus AVD for Untreated Classical Hodgkin Lymphoma - OncLive
FDA Approves Nivolumab Plus AVD for Untreated Classical Hodgkin Lymphoma OncLive
Nivolumab/AVD: A New Standard in Untreated Advanced Hodgkin Lymphoma - CancerNetwork
Nivolumab/AVD: A New Standard in Untreated Advanced Hodgkin Lymphoma CancerNetwork
Nivolumab Plus AVD Reduces Disease Progression Risk in Adolescents With Advanced Classical Hodgkin Lymphoma - The ASCO Post
Nivolumab Plus AVD Reduces Disease Progression Risk in Adolescents With Advanced Classical Hodgkin Lymphoma The ASCO Post
Low-Dose Nivolumab Offers Novel Strategy for Hodgkin Lymphoma Treatment - Targeted Oncology
Low-Dose Nivolumab Offers Novel Strategy for Hodgkin Lymphoma Treatment Targeted Oncology
Primary extranodal marginal zone non-hodgkin lymphoma of the prostate: a case report - Frontiers
Primary extranodal marginal zone non-hodgkin lymphoma of the prostate: a case report Frontiers
Non-Hodgkin's Lymphoma Market Size to Hit USD 26.22 Billion by 2035 - Precedence Research
Non-Hodgkin's Lymphoma Market Size to Hit USD 26.22 Billion by 2035 Precedence Research
Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors - Nature
Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors Nature
Non-Hodgkin lymphoma survivor thankful for clinical trial - UT MD Anderson
Non-Hodgkin lymphoma survivor thankful for clinical trial UT MD Anderson
Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era - CancerNetwork
Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era CancerNetwork
Outlining Common Drawbacks to Prior Standards for Hodgkin Lymphoma - CancerNetwork
Outlining Common Drawbacks to Prior Standards for Hodgkin Lymphoma CancerNetwork
Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma - Nature
Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma Nature
Stage IV non-Hodgkin lymphoma survivor: Why I’m excited about UT MD Anderson coming to Austin - UT MD Anderson
Stage IV non-Hodgkin lymphoma survivor: Why I’m excited about UT MD Anderson coming to Austin UT MD Anderson
FDA Approves Nivolumab/AVD in Untreated Hodgkin Lymphoma - CancerNetwork
FDA Approves Nivolumab/AVD in Untreated Hodgkin Lymphoma CancerNetwork
Learn About How Survival Rates Are Improving With Hodgkin Disease - Verywell Health
Learn About How Survival Rates Are Improving With Hodgkin Disease Verywell Health
Nodular lymphocyte-predominant Hodgkin lymphoma: Leah's story - Roswell Park Comprehensive Cancer Center
Nodular lymphocyte-predominant Hodgkin lymphoma: Leah's story Roswell Park Comprehensive Cancer Center
Young mother’s Hodgkin lymphoma diagnosis felt ‘devastating’ - Fred Hutchinson Cancer Center
Young mother’s Hodgkin lymphoma diagnosis felt ‘devastating’ Fred Hutchinson Cancer Center
Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials - Nature
Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials Nature
FDA Approves BMY's Opdivo Label Expansion in Classical Hodgkin Lymphoma - Yahoo Finance
FDA Approves BMY's Opdivo Label Expansion in Classical Hodgkin Lymphoma Yahoo Finance
Consecutive approvals of Opdivo for Hodgkin’s lymphoma to boost sales growth - Clinical Trials Arena
Consecutive approvals of Opdivo for Hodgkin’s lymphoma to boost sales growth Clinical Trials Arena
Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates - Iowa Capital Dispatch
Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates Iowa Capital Dispatch
FDA OKs Upfront Nivolumab+Chemo for Classic Hodgkin Lymphoma - Medscape
FDA OKs Upfront Nivolumab+Chemo for Classic Hodgkin Lymphoma Medscape
Hodgkin Lymphoma (HL): Microenvironmental Biology Behind a Therapeutic Success Story - Oncodaily
Hodgkin Lymphoma (HL): Microenvironmental Biology Behind a Therapeutic Success Story Oncodaily
Non-Hodgkin Lymphoma Treatment Market Size, Forecast, 2034 - Fortune Business Insights
Non-Hodgkin Lymphoma Treatment Market Size, Forecast, 2034 Fortune Business Insights
US FDA approves Bristol Myers Squibb's cancer drug for Hodgkin's lymphoma - Reuters
US FDA approves Bristol Myers Squibb's cancer drug for Hodgkin's lymphoma Reuters
Durable 3-Year Superiority of N-AVD in Advanced Hodgkin Lymphoma - Targeted Oncology
Durable 3-Year Superiority of N-AVD in Advanced Hodgkin Lymphoma Targeted Oncology
New Phase 3 Clinical Trial Opens for Pediatric, Adult Hodgkin Lymphoma Patients - Roswell Park Comprehensive Cancer Center
New Phase 3 Clinical Trial Opens for Pediatric, Adult Hodgkin Lymphoma Patients Roswell Park Comprehensive Cancer Center
Brentuximab Vedotin Combo Exhibits Efficacy in Early-Stage Hodgkin Lymphoma - CancerNetwork
Brentuximab Vedotin Combo Exhibits Efficacy in Early-Stage Hodgkin Lymphoma CancerNetwork
Lymphocyte Kinetics After CAR T-Cell Infusion May Predict Survival Outcomes in Non-Hodgkin Lymphoma - The ASCO Post
Lymphocyte Kinetics After CAR T-Cell Infusion May Predict Survival Outcomes in Non-Hodgkin Lymphoma The ASCO Post
‘The Sister Act’: How family and faith helped a young woman beat Hodgkin’s lymphoma - University of California - Davis Health
‘The Sister Act’: How family and faith helped a young woman beat Hodgkin’s lymphoma University of California - Davis Health
Impact of early failure of induction on transplant outcomes in Hodgkin lymphoma | Bone Marrow Transplantation - Nature
Impact of early failure of induction on transplant outcomes in Hodgkin lymphoma | Bone Marrow Transplantation Nature
Axi-Cel Shows Durable Responses, Curative Hope in Non-Hodgkin Lymphoma - Targeted Oncology
Axi-Cel Shows Durable Responses, Curative Hope in Non-Hodgkin Lymphoma Targeted Oncology
Vanishing Bile Duct Syndrome as a Rare Complication of Classic Hodgkin's Lymphoma: A Case Report and Literature Review - Cureus
Vanishing Bile Duct Syndrome as a Rare Complication of Classic Hodgkin's Lymphoma: A Case Report and Literature Review Cureus